Several analysts have recently updated their ratings and price targets for Aduro BioTech (NASDAQ: ADRO): 9/9/2015 – Aduro BioTech was upgraded by analysts at Zacks from a “sell” rating to a “hold” rating. According to Zacks, “Aduro Biotech, Inc. is an immunotherapy company. The Company develops technology and vaccines for the treatment of cancer and […]
